Assessing methods to adjust for assay differences across COVID-19 serological surveillance studies in Canada

Jiacheng Chen1,2, …, W. Alton Russell1,2

1School of Population and Global Health, McGill University, Montreal, Canada

2COVID-19 Immunity Task Force

**Corresponding author:**

**Key words:**

**Running title:**

# Abstract

**Background:** A

**Methods:** A

**Results:** A

**Conclusions:** A

# Introduction

Citation [1]. See [Figure 1](#fig-sample), [Table S 1](#cor-sample), [Table 1](#thm-sample), and [Figure S 1](#lem-sample).

# Methods

## Subsection

A

# Results

A

# Discussion

A

# Declarations

**Funding:** A

**Conflicts:** A

**Ethics/Consent:** A

**Data and materials:** A

**Code availability:** A

**Authors’ contributions: A**

# References

1. Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. *Value in Health*. 2018;21(4):407-415. doi:[10.1016/j.jval.2017.07.014](https://doi.org/10.1016/j.jval.2017.07.014)

# Tables

**Table 1** Table caption here.

| **col1** | **col2** |
| --- | --- |
| **A** | |
| 1 | Yes |
| 2 | Yes |
| **B** | |
| 1 | No |
| 2 | No |

# Figures

|  |
| --- |
| **Figure** 1: Figure caption here. |

# Supplemental materials

# A. Supplement section

# Supplemental tables

**Table S 1** Table caption here.

| **col1** | **col2** |
| --- | --- |
| **A** | |
| 1 | Yes |
| 2 | Yes |
| **B** | |
| 1 | No |
| 2 | No |

# Supplemental figures

**Figure S 1** Figure caption here.

